



# Ballot Vote Sheet

**TO:** The Commission  
Alberta E. Mills, Secretary

**DATE:** July 26, 2023

**THROUGH:** Austin C. Schlick, General Counsel  
Jason K. Levine, Executive Director

**FROM:** Elisabeth Layton, Attorney, Regulatory Affairs  
Daniel R. Vice, Assistant General Counsel, Regulatory Affairs

**SUBJECT:** *Federal Register* Notice of Availability of Proposed  
Supplemental Guidance for CPSC Chronic Hazard Guidelines

**BALLOT VOTE DUE:** Tuesday, August 1, 2023

Attached for the Commission’s consideration is a draft *Federal Register* notice of availability of proposed supplemental guidance for CPSC’s Chronic Hazard Guidelines. In 1992, the Commission issued the Guidelines for assessing chronic hazards under the Federal Hazardous Substances Act (FHSA), including carcinogenicity, neurotoxicity, reproductive/developmental toxicity, exposure, bioavailability, risk assessment, and acceptable risk.

The Guidelines are intended to assist firms in identifying products that present chronic hazards, to meet their labeling obligations under the FHSA and the Labeling of Hazardous Art Materials Act. They are not binding on industry or on the Commission. Since the Guidelines were issued in 1992, however, there have been numerous advances in the basic science underlying them. In addition, there have been several changes in the practice of risk assessment. Therefore, staff is proposing two guidance documents to supplement the 1992 Guidelines. The first supplement provides guidance for the application of benchmark dose methodology to risk assessment. The second supplement provides guidance for analysis of uncertainty and variability, including use of probabilistic risk assessment methodology. The attached draft *Federal Register* notice would alert the public to the availability of these two proposed guidance documents and invite comments on them before the Commission finalizes any supplemental guidance.

Please indicate your vote on the following options: Approve publication of the attached document in the *Federal Register*, as drafted.

**U.S. Consumer Product  
Safety Commission**  
4330 East-West Highway  
Bethesda, MD 20814

**National Product Testing  
& Evaluation Center**  
5 Research Place  
Rockville, MD 20850

[cpsc.gov](http://cpsc.gov)

THIS DOCUMENT HAS NOT BEEN REVIEWED  
OR ACCEPTED BY THE COMMISSION

CLEARED FOR PUBLIC RELEASE  
UNDER CPSA 6(b)(1)



# Ballot Vote Sheet

\_\_\_\_\_  
(Signature)

\_\_\_\_\_  
(Date)

I. Approve publication of the attached document in the *Federal Register*, with the specified changes.

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

\_\_\_\_\_  
(Signature)

\_\_\_\_\_  
(Date)

II. Do not approve publication of the attached document in the *Federal Register*.

\_\_\_\_\_  
(Signature)

\_\_\_\_\_  
(Date)

III. Take other action specified below.

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

\_\_\_\_\_  
(Signature)

\_\_\_\_\_  
(Date)

Attachment: Draft *Federal Register* notice, Notice of Availability of Proposed Supplemental Guidance for CPSC Chronic Hazard Guidelines

**U.S. Consumer Product  
Safety Commission**  
4330 East-West Highway  
Bethesda, MD 20814

**National Product Testing  
& Evaluation Center**  
5 Research Place  
Rockville, MD 20850

[cpsc.gov](http://cpsc.gov)

THIS DOCUMENT HAS NOT BEEN REVIEWED  
OR ACCEPTED BY THE COMMISSION

CLEARED FOR PUBLIC RELEASE  
UNDER CPSA 6(b)(1)

[Billing Code 6355-01-P]

**CONSUMER PRODUCT SAFETY COMMISSION**

**Notice of availability: Proposed Supplemental Guidance for CPSC Chronic Hazard Guidelines**

**[Docket No. CPSC-2023-XXXX]**

**AGENCY:** U.S. Consumer Product Safety Commission.

**ACTION:** Notification of availability and request for comment.

**SUMMARY:** The Consumer Product Safety Commission (Commission or CPSC) is announcing the availability of proposed supplemental guidance for its Chronic Hazard Guidelines. The supplements are (1) draft supplemental guidance for the use of benchmark dose methodology in risk assessment, and (2) draft supplemental guidance for the analysis of uncertainty and variability in risk assessment. The Commission requests comments from the public on the proposed supplemental guidance.

**DATES:** Submit comments by [INSERT DATE **60 DAYS** AFTER DATE OF PUBLICATION IN THE *FEDERAL REGISTER*].

**ADDRESSES:** You can submit comments, identified by Docket No. CPSC-2023-**00XX**, by any of the following methods:

*Electronic Submissions:* Submit electronic comments to the Federal eRulemaking Portal at [www.regulations.gov](http://www.regulations.gov). Follow the instructions for submitting comments. Do not submit through this website: confidential business information, trade secret information, or other sensitive or protected information that you do not want to be available to the public. CPSC typically does not accept comments submitted by electronic mail (email), except as described below.

*Mail/Hand Delivery/Courier/Confidential Written Submissions:* CPSC encourages you to submit electronic comments by using the Federal eRulemaking Portal. You may, however,

**OS 4**  
**DRAFT**

submit comments by mail, hand delivery, or courier to: Office of the Secretary, Consumer Product Safety Commission, 4330 East West Highway, Bethesda, MD 20814; telephone: (301) 504-7479.

*Instructions:* All submissions must include the agency name and docket number. CPSC may post all comments without change, including any personal identifiers, contact information, or other personal information provided to [www.regulations.gov](http://www.regulations.gov). If you wish to submit confidential business information, trade secret information, or other sensitive or protected information that you do not want to be available to the public, you may submit such comments by mail, hand delivery, or courier, or you may email them to: [cpsc-os@cpsc.gov](mailto:cpsc-os@cpsc.gov).

*Docket:* For access to the docket to read background documents or comments received, go to [www.regulations.gov](http://www.regulations.gov), and insert the docket number, CPSC-2023-00XX, into the “Search” box, and follow the prompts. The proposed supplemental guidance is available under “Supporting and Related Material.” It is also available on the Commission’s website at: \_\_\_\_\_, and from the Commission’s Office of the Secretary.

**FOR FURTHER INFORMATION CONTACT:** Eric Hooker, Directorate for Health Sciences, U.S. Consumer Product Safety Commission, 5 Research Place, Rockville, MD 20850; telephone: (301) 987-2516; email: [ehooker@cpsc.gov](mailto:ehooker@cpsc.gov).

**SUPPLEMENTARY INFORMATION:**

**A. Background**

In 1992 the Commission issued guidelines for assessing chronic hazards under the Federal Hazardous Substances Act (FHSA), including carcinogenicity, neurotoxicity, reproductive/developmental toxicity, exposure, bioavailability, risk assessment, and acceptable risk. 57 FR 46626 (summarized in 16 CFR 1500.135).

**OS 5**  
**DRAFT**

Determining whether a product is or contains a hazardous substance involves scientific analysis, legal interpretation, and the application of policy judgment. The Guidelines are intended to assist firms in identifying products that present chronic hazards, to meet their labeling obligations under the FHSA and the Labeling of Hazardous Art Materials Act (LHAMA). They are not binding on industry or the Commission. Indeed, chronic toxicity may be established in various ways. The Commission may determine that a product is a hazardous substance due to a chronic hazard based on any evidence that is relevant and material to such a determination.

For example, peer-reviewed scientific studies by third parties and toxicity assessments from CPSC's peer agencies may be relevant and material evidence to establish chronic toxicity and that a substance is a "hazardous substance" under the FHSA. Likewise, evidence from third parties may be useful to determine chronic toxicity. For instance, third party studies may indicate that chronic adverse health effects are associated with foreseeable levels of consumer exposure, allowing the Commission to conclude that the FHSA's criteria for a "hazardous substance" are satisfied. Other cases, however, may require CPSC to undertake original research to fill gaps in knowledge.

In addition, while the Guidelines describe certain toxic endpoints, they do not limit the toxic endpoints the Commission may consider. The Commission may consider all forms of personal injury or illness as potential toxic endpoints.

The chronic hazard guidelines, which should be understood as a set of best practices, are not mandatory for the Commission or for stakeholders. The guidelines describe methods that CPSC staff may use to assess chronic hazards under the FHSA. Furthermore, the guidelines are intended to be sufficiently flexible to incorporate the latest scientific information, such as

**OS 6**  
**DRAFT**

advances in risk assessment methodology. Risk assessors may deviate from the default assumptions described in the guidelines, provided that their methods and assumptions are documented, scientifically defensible, and supported by appropriate data as in indicated in section VI.A.2 of the preamble of the guidelines (57 FR 46633). However, given that the guidelines represent an available set of best practices, risk assessors are encouraged to use the information and approaches outlined therein where appropriate.

In the years since the guidelines were issued, there have been numerous advances in the basic science underlying the guidelines, such as the use of transgenic animals to elucidate mechanisms of carcinogenicity and toxicity. There also have been several changes in the practice of risk assessment, including wider acceptance and use of risk assessment methods such as the benchmark dose approach and probabilistic exposure assessment. Therefore, CPSC is proposing two guidance documents to supplement the 1992 guidelines.<sup>1</sup>

The first supplement provides guidance for the application of benchmark dose methodology (BMD) to risk assessment. This supplement discusses an alternative to the traditional approach described in the original guidelines for estimating acceptable daily intakes (ADIs) for carcinogenic and other hazards, such as neurotoxicological or reproductive/developmental hazards (*see* 57 FR 46654 (section VI.F.3.b.ii) and 57 FR 46656 (section VI.F.4.b.1.ii)). The second supplement is guidance for the analysis of uncertainty and variability, including use of probabilistic risk assessment methodology, which is most relevant to exposure assessment (*see* 57 FR 46644 (section VI.F.1 of the preamble)).

Like the 1992 guidelines, the proposed supplemental guidance documents are not mandatory. Rather, they describe the methods that CPSC staff use to evaluate chronic hazards

---

<sup>1</sup> The proposed guidance documents are available at: [WEB ADDRESS].

and which manufacturers could use. The guidelines are intended to assist manufacturers in complying with the requirements of the FHSA and to facilitate the use of reliable risk assessment methodologies by both manufacturers and CPSC staff.

**B. Request for comments**

The Commission invites comments on the proposed guidance supplementing CPSC's Chronic Hazard Guidelines with respect to the use of benchmark dose methodology in risk assessment and analysis of uncertainty and variability in risk assessment.

The CPSC will consider all timely comments before finalizing the supplemental guidance. Comments should be submitted by **[Insert date 60 days after date of publication in the Federal Register]**. Information on how to submit comments can be found in the ADDRESSES section of this notice.

---

Alberta E. Mills, Secretary

Consumer Product Safety Commission



## Memorandum

**TO:** The Commission  
Alberta E. Mills, Secretary

**DATE:** July 26, 2023

**THROUGH:** Austin C. Schlick, General Counsel  
Jason K. Levine, Executive Director  
DeWane Ray, Deputy Executive Director for Operations

**FROM:** Duane Boniface, Assistant Executive Director for Hazard Identification and Reduction  
Eric Hooker, M.S., D.A.B.T., Division of Toxicology & Risk Assessment

**SUBJECT:** Proposed Supplemental Guidance for the CPSC Chronic Hazard Guidelines: Benchmark Dose Methodology and Analysis of Uncertainty and Variability

---

## Background

In 1992, the U.S. Consumer Product Safety Commission (CPSC) issued guidelines for assessing chronic hazards under the Federal Hazardous Substances Act (FHSA), including carcinogenicity, neurotoxicity, reproductive/developmental toxicity, exposure, bioavailability, risk assessment, and acceptable risk.<sup>1</sup> The chronic hazard guidelines, which should be understood as a set of best practices, are intended to assist manufacturers in complying with the FHSA and the Labeling of Hazardous Art Materials Act (LHAMA). These guidelines are not mandatory for the Commission or for stakeholders. The guidelines describe methods that CPSC staff may use to assess chronic hazards under the FHSA. Furthermore, the guidelines are intended to be sufficiently flexible to incorporate the latest scientific information, such as advances in risk assessment methodology. Risk assessors may deviate from the default assumptions described in the guidelines, provided that their methods and assumptions are documented, scientifically defensible, and supported by appropriate data (CPSC 1992, § VI.A.2). However, given that the guidelines represent an available set of best practices, risk assessors are encouraged to use the information and approaches outlined therein where appropriate.

---

<sup>1</sup> 57 FR 46626 (Oct. 9, 1992.) The guidelines are available at [https://www.cpsc.gov/s3fs-public/pdfs/blk\\_pdf\\_chronichazardguidelines.pdf](https://www.cpsc.gov/s3fs-public/pdfs/blk_pdf_chronichazardguidelines.pdf). They are summarized at 16 C.F.R. §1500.135.



In the years since the guidelines were issued, there have been numerous advances in the basic science underlying the guidelines, such as the use of transgenic animals<sup>2</sup> to elucidate mechanisms of carcinogenicity and toxicity. There also have been several changes in the practice of risk assessment, including wider acceptance and use of risk assessment methods such as the benchmark dose approach and probabilistic exposure assessment, as described below. Therefore, CPSC staff is proposing two supplemental guidance documents be posted on the CPSC website along with the 1992 guidelines. Both documents were peer-reviewed by experts in the respective methods.

The first supplement provides guidance for the application of benchmark dose methodology (BMD) to risk assessment (TAB A). This supplement discusses an alternative to the traditional approach described in the original guidelines for estimating acceptable daily intakes (ADI's) for carcinogenic (57 FR 46,656 (Oct. 9, 1992), at §VI.F.3.b.ii of the preamble) and other (e.g., neurotoxicological, reproductive/developmental) (§VI.F.4.b.1.ii.) hazards. The second supplement is guidance for the analysis of uncertainty and variability, including use of probabilistic risk assessment methodology (PRA), which is most relevant to exposure assessment (§VI.F.1.) (TAB B). Both of the supplements were peer reviewed in 2008 by two independent scientists with expertise in either BMD or PRA. The practice of BMD and PRA have not fundamentally changed since the supplements were peer-reviewed.

Like the 1992 guidelines, the proposed supplemental guidance documents are not mandatory. Rather, they describe the methods that CPSC staff use to evaluate chronic hazards and which manufacturers could use. The guidelines are intended to assist manufacturers in complying with the requirements of the FHSA and to facilitate the use of reliable risk assessment methodologies by both manufacturers and CPSC staff.

CPSC staff is requesting the Commission publish a notice of availability to obtain public comments on the proposed supplements. Staff will then respond to the public comments and finalize the supplements, as appropriate. After the supplements are finalized, they will be posted on the CPSC website with the original guidelines for use by interested parties. In addition, the summary at 16 C.F.R. §1500.135 will be amended.

## The Proposed Supplements

### Benchmark Dose

A long-standing, traditional method of deriving acceptable daily intake (ADI) levels for non-cancer health effects is to use the “no observed adverse effect level” (NOAEL) or “lowest observed adverse effect level” (LOAEL) from a toxicity study in laboratory animals as a “point of departure” (POD). The NOAEL is the highest dose in a toxicity study at which no adverse health effects are observed; the LOAEL is the lowest dose at which adverse effects are observed. The NOAEL or LOAEL is divided by uncertainty factors to account for potential differences in sensitivity between the tested laboratory animals and humans, as well as for differences within the human population, including vulnerable populations. For example, suppose the NOAEL in an animal study is 100 milligrams of chemical per kilogram of the test animal's body weight per day (mg/kg-d). The ADI is typically the NOAEL divided by 10 for animal to human differences, and another factor of 10 for vulnerable populations. Thus, the

---

<sup>2</sup> Genetically modified animals that detect carcinogens more rapidly (in a few months) than the traditional two-year bioassay.

human ADI is 1 mg per kg of body weight per day (mg/kg-d). The LOAEL is used only when a NOAEL has not been established, in which case, an additional uncertainty factor is applied.

There are certain disadvantages to this traditional method. First, the ADI depends, in part, on the doses that the toxicologist chose to test in the underlying toxicity study. Thus, the method makes it difficult to compare the toxicities of different chemicals. Second, if the study did not identify a NOAEL, the additional 10-fold uncertainty factor may underestimate or overestimate the NOAEL. Third, the likelihood of observing an adverse health effect at a given dose depends on the number of animals tested. Thus, for example, a study using 5 animals per dose level has a lower chance of identifying an adverse effect than a study using 50 animals per dose level. Therefore, the traditional method rewards smaller studies, while providing a less robust estimate of the point of departure.

BMD is an alternative to the traditional method. BMD uses a mathematical dose response model to estimate a “benchmark dose,” that is, a dose at which a given percentage of the tested laboratory animals (usually 5 or 10%) exhibits an observable adverse effect. The BMD is then divided by appropriate uncertainty factors to calculate the ADI. The BMD method has several advantages. First, studies that differ only in the choice of experimental doses will have roughly the same BMD. Second, the additional uncertainty factor for use of the LOAEL (if a NOAEL is not observed) is not needed because the method does not rely on only a LOAEL. Third, smaller studies are not rewarded, because smaller studies (studies with fewer animals) tend to have larger confidence intervals (i.e., greater uncertainty). Fourth, BMD uses all chemical doses tested from the toxicity study, rather than just a single dose. Fifth, BMD can be used for both cancer and non-cancer endpoints.

The proposed supplemental guidance discusses factors such as the choice of mathematical model, default values for the choice of benchmark dose, and statistical details such as the use of “extra risk,” as opposed to “additional risk.”

### Analysis of Uncertainty and Variability

Probabilistic risk assessment is an approach for assessing variability and uncertainty in risk assessments. In practice, probabilistic risk assessment is primarily applied to exposure assessment. Exposure assessment is a critical step in the risk assessment process. Exposure assessment is “the process of measuring or estimating the intensity, frequency, and duration of human exposures to an agent currently present in the environment or of estimating hypothetical exposures that might arise from the release of new chemicals into the environment. Exposure may be defined as the “[c]ontact made between a chemical, physical, or biological agent and the outer boundary of an organism.”<sup>3</sup> Exposure assessment is the “identification and evaluation of the human population exposed to a toxic agent, describing its composition and size, as well as the type, magnitude, frequency, route and duration of exposure.” Exposure may be assessed by direct measurements such as the concentration of a chemical in indoor air, amount on the skin, or the amount present in an individual’s blood or urine. In most cases, however, direct measurements are not available. In these cases, exposure is assessed through mathematical models that combine several variables describing the factors that influence exposure. For example, an assessment of exposure to a chemical released into the air during use of a product may include information about the emission rate into the air, the resulting concentration of the chemical in the air, the amount of time a person spends using the product or time spent living, working, or playing in the area, and the amount of air a person breathes during the exposure.

---

<sup>3</sup> U.S. EPA Iris Glossary. <https://www.epa.gov/iris/iris-glossary#e> Accessed January 2023.

Human exposure assessments most commonly employ a “deterministic” approach, in which exposures are expressed in the form of “point estimates.” Point estimates are generally expressed as a single estimate of exposure, such as a measure of the average or a “reasonable worst case” exposure. As an alternative to the point estimate, probabilistic methods can generate a distribution of exposures in a population. The distribution reflects information on variability and uncertainty. Uncertainty results from the inherent errors in measurements (e.g., the concentration of a chemical in air) or sampling error (measuring exposure in a sample of the population of interest). Variability reflects the variation of exposure among different individuals. Variability may be due to differences in the frequency of product use, as well as physiological differences (e.g., body weight, activity level).

The primary advantage of a probabilistic approach is the generation of information on the distribution of exposure and risk in a population, in addition to estimates of the average exposure and risk. This provides information on the range of exposures, including highly exposed individuals. In addition, the probabilistic approach can be used to estimate the percentage of the population that exceeds the acceptable daily intake level. Another advantage is the ability to generate confidence intervals for exposure estimates. For example, the average or 95<sup>th</sup> percentile exposure can be expressed as  $X \pm Y$ , which provides a measure of uncertainty in the estimated exposure.

The proposed supplemental guidance on probabilistic risk assessment discusses factors such as data needs, when it is appropriate to use probabilistic methods, and sensitivity analysis.

## Discussion

Like the 1992 guidelines, the proposed supplemental guidance documents are not mandatory. Rather, they describe established methods CPSC staff and stakeholders could use to evaluate chronic hazards. The guidelines are intended as an aid to manufacturers in making their determination of whether a product is a hazardous substance due to chronic toxicity, and thus would require labeling under the FHSA and to facilitate the availability and use of reliable risk assessment methodologies for both manufacturers and CPSC staff.

## Contents

- TAB A. Draft Supplemental Guidance for the Use of Benchmark Dose Methodology in Risk Assessment.
- TAB B. Draft Supplemental Guidance for the Analysis of Uncertainty and Variability in Risk Assessment.

**TAB A: Draft Supplemental Guidance for the Use of  
Benchmark Dose Methodology in Risk Assessment**

**T  
A  
B  
  
A**

# DRAFT SUPPLEMENTAL GUIDANCE FOR THE USE OF BENCHMARK DOSE METHODOLOGY IN RISK ASSESSMENT<sup>4</sup>

## BACKGROUND

In 1992, the U.S. Consumer Product Safety Commission (CPSC) issued guidelines for assessing chronic hazards under the Federal Hazardous Substances Act (FHSA) and the Labeling of Hazardous Art Materials Act (LHAMA), including carcinogenicity, neurotoxicity, reproductive/developmental toxicity, exposure, bioavailability, risk assessment, and acceptable risk (CPSC 1992).<sup>5</sup> The chronic hazard guidelines, which are not mandatory for CPSC or stakeholders, are intended as an aid to manufacturers in making their determination of whether a product is a hazardous substance due to chronic toxicity, and thus would require labeling under the FHSA. The guidelines describe methods that CPSC staff use to assess chronic hazards under the FHSA. Furthermore, the guidelines are intended to be sufficiently flexible to incorporate the latest scientific information, such as advances in risk assessment methodology. Risk assessors may deviate from the default assumptions described in the guidelines, provided that their methods and assumptions are documented, scientifically defensible, and supported by appropriate data. However, given that the guidelines represent an available set of best practices, risk assessors are encouraged to use the information and approaches outlined therein where appropriate, and other methods will be reviewed by staff to determine acceptability.

In the years since the guidelines were issued, there have been numerous advances in the basic science underlying the guidelines, such as the use of alternative methods to elucidate mechanisms of carcinogenicity and toxicity. There also have been several changes in the practice of risk assessment, such as in the assessment of risks to children, as well as wider acceptance and use of risk assessment methods such as the benchmark dose approach and probabilistic exposure assessment. Therefore, CPSC staff-initiated reviews of the existing chronic hazard guidelines and is recommending additions or changes, as appropriate. The purpose of this document is to describe supplemental guidance for the application of the benchmark dose approach in risk assessment.

The current scientific knowledge regarding the risk assessment of chronic hazards is such that the guidelines cannot be applied mechanically (CPSC 1992, Section VI.A.2, page 46633). Rather, considerable expertise and professional judgment are required to apply the guidelines properly. Furthermore, the volume of scientific literature on chronic hazard risk assessment, in general, and the benchmark dose, in particular, is extensive. Therefore, the discussion and guidance described below are not intended to explain how to perform chronic hazard risk assessments using the methods described. The guidelines assume that the reader has the necessary expertise. In addition, the discussion presented here is necessarily brief. The risk assessor is referred to the literature on benchmark dose, only a portion of which is cited here.

---

<sup>4</sup> These draft guidelines were developed by CPSC staff, and they have not been reviewed or approved by, and may not reflect the views of, the Commission.

<sup>5</sup> The current guidelines are summarized at 16 C.F.R. § 1500.135.

## DISCUSSION

The benchmark dose (BMD) approach (Crump 1984a; Crump et al. 1995) is an alternative to the traditional method of deriving acceptable daily intake (ADI)<sup>6</sup> levels by using no observed adverse effect levels (NOAELs)<sup>7</sup> and lowest observed adverse effect levels (LOAELs). The BMD may be used for both cancer and non-cancer endpoints, quantal or continuous data, and animal or human data. The BMD is an estimate of the dose level for a particular response. For example, the BMD<sub>10</sub> is the best estimate of the dose at an excess risk (risk over background) of 10%, and the BMDL<sub>10</sub> is the lower confidence limit (LCL) of the BMD<sub>10</sub>. The benchmark response (BMR) level is the response level selected for deriving an ADI level or cancer unit risk (slope factor).<sup>8</sup> The BMR is within or near the observable range of the bioassay used to derive the ADI or unit risk. Typically, selected BMR's range from 1% to 10% excess risk. To derive an ADI for non-cancer endpoints, the BMD is divided by the same uncertainty (safety) factors that are normally applied to the NOAEL. For cancer risk, the BMD is used as a "point of departure" (PoD) for linear extrapolation to the background level (EPA 2005). However, uncertainty factors may be applied for cancer risk if there is convincing evidence for a non-linear dose response at low doses.

### Advantages of the BMD Approach

The advantages of the BMD approach have been described in detail elsewhere (Barnes et al. 1995; Crump 1984a; Crump et al. 1995; Gaylor et al. 1998; EPA, 2012; Filipsson et al. 2003). For example, the NOAEL and LOAEL are limited to the doses tested in the bioassay. In contrast, the BMD is not limited to the doses tested in the bioassay. Thus, the BMD provides a more consistent basis for comparisons between studies that did not use the same dose levels.

The true (parametric) value of the BMD is independent of the study design, such as the number of animals per dose group,  $n$ . However, the NOAEL is sensitive to  $n$ . The NOAEL is not a threshold, although it is frequently regarded as such. Rather, it is more appropriate to regard the NOAEL as a limit of detection. The incidence of adverse effects may be as high as 20% at the NOAEL. A given dose level may be a NOAEL in a study with small  $n$  if the incidence is not significantly different from background. However, the same dose in a larger study may be a LOAEL due to the increased sensitivity resulting from a larger  $n$ . The traditional NOAEL approach "rewards" studies with small  $n$ , by resulting in higher (i.e., less protective) NOAELs. Conversely, the traditional approach "penalizes" studies with larger  $n$ , by resulting in lower (more protective) NOAELs. Thus, the traditional method is a disincentive to performing better, larger studies. In contrast, the BMD is essentially independent of  $n$  and, therefore, does not penalize studies with a larger  $n$ .

The BMD approach may account for variability in the bioassay. If the BMDL is used, larger studies tend to have smaller confidence intervals. Thus, larger studies are generally rewarded, because a smaller confidence interval leads to a higher BMDL. In contrast, poorly designed studies with inadequate sample size are penalized by having larger confidence intervals, leading to a lower BMDL.

---

<sup>6</sup> The ADI is an estimate of the amount of a chemical a person can be exposed to on a daily basis over an extended period of time (up to a lifetime) with a negligible risk of suffering deleterious effects. The ADI is roughly equivalent to a "reference dose" or "tolerable daily intake."

<sup>7</sup> In the chronic hazard guidelines, "NOEL" is used synonymously with "NOAEL," because only adverse effects are relevant under the FHSA.

<sup>8</sup> The term "unit risk" is used synonymously with "slope factor" (CPSC 1992).

The BMD accounts for the slope and shape of the dose response curve and uses all of the dose response data from the study. In contrast, the NOAEL or LOAEL relies on the response at only one dose level. Thus, information on the slope and shape of the dose response curve is ignored.

With the BMD approach, the methodology is the same regardless of whether a NOAEL is established. An additional uncertainty factor that is generally applied when using the LOAEL is not required in a BMD analysis, because the BMD can still be estimated even if a NOAEL has not been established.

While there are several advantages to the BMD approach, the principal disadvantage is the added complexity of the methodology. BMD methods require expertise in statistics, as well as toxicology. The additional steps involved in the analysis also increases the number of decision points, such as the choice of BMD and mathematical model, which require professional judgment. This, in turn, increases the number and possibly the range of possible ADI values from a given data set and may lead to areas of disagreement among risk assessors.

### BMD Methodology

While the overall BMD approach is straightforward, there are many factors that must be considered in applying BMD methods in risk assessment, including the selection of the most appropriate endpoint and data set, dose response model, statistical methods, and selection of the BMD. Each of these factors requires knowledge of toxicology and risk assessment, as well as professional judgment.

#### **Selection of the Endpoint and Data Set to Model**

Initially, the selection of the critical study and endpoint to model is similar to the traditional approach. The study should be well-designed and executed, with an adequate number of animals and doses, and a statistically significant effect (CPSC 1992, Sections VI.C.3.a, p. 46639; VI.C.3.b, p. 46640; VI.D.2.a, p. 46642; and VI.D.3.b, p. 46643). There should be a dose where there are no observed adverse effects, i.e., at or near the NOAEL. The selection of the critical endpoint is based, in part, on the judgment of the toxicologist or pathologist regarding the biological significance of the endpoint. When multiple studies, multiple endpoints, or multiple species are available, generally the most sensitive dose response is used (CPSC 1992, Section F.4.b.ii, p. 46656).

It should be noted that the study with the lowest NOAEL will not necessarily lead to the lowest BMD, because the BMD also depends on the slope of the dose-response curve. Therefore, all relevant endpoints and studies should be modeled (Filipsson et al. 2005) to ensure that the lowest BMD is identified.

Additionally, the data set must be amenable to modeling. That is, there should be a steadily increasing dose response that is not saturated at the high doses. If none of the available dose response models can adequately fit the data (see below), the BMD approach cannot be used.

#### **Selection of the Dose Response Model**

The BMD approach is essentially a curve-fitting exercise. The choice of the dose-response model does not require any knowledge of the mode of action. Thus, the form of the model is not necessarily prescribed or dictated by any specific information about the studied activity, provided that it adequately describes the data. In some instances, however, mechanistic information may suggest a particular model, such as the Hill model when cooperative binding is observed.



A variety of dose-response models have been used to estimate the BMD (Crump 1984a; Crump et al. 1995; EPA 2022; Filipsson et al. 2003; Gaylor et al. 1998). The BMD approach may be applied to either quantal (dichotomous) or continuous data. Incidence data, such as the number of animals with a certain adverse effect, are quantal. Serum enzyme or hormone levels are examples of continuous data. Generally, quantal and continuous data require different, though related, dose response models. Nested quantal models may be used with developmental studies to evaluate effects within and between litters.

Dose response models for quantal data include linear (one-hit), quadratic, gamma multi-hit, Weibull, polynomial (multistage), logistic, log-logistic, probit, and log-probit models. These are slightly modified versions of the dose response models that have been used for cancer risk assessment (compare Crump 1984b; Zeise et al. 1987). The linear, quadratic, and Weibull models are essentially subsets of the polynomial model. Therefore, some or all of these models may yield similar results for certain data sets, such as when the dose response is linear. Dose response models for continuous data include linear, quadratic, linear-quadratic, polynomial, power, and Hill models. In addition, nested models are available for developmental studies. The mathematical forms of the models are described in detail elsewhere (Crump 1984a; Crump et al. 1995; EPA 2022; Filipsson et al. 2003; Gaylor et al. 1998).

In applying the BMD approach to non-cancer endpoints, the dose response models are not used for low-dose extrapolation. Thus, in contrast to cancer risk assessment, there is no need to consider the shape of the curve at low doses. Therefore, the choice of dose response model depends, in large part, on the goodness of fit. That is, the model (or models) selected must adequately describe the data. A model is generally rejected if the probability based on chi-square is less than 0.05. In other words, if the probability that the deviation of the data from the model is due to random variability is less than 0.05, the model does not adequately describe the data. Depending on the data set, multiple models may provide a similar global fit to the data. In this case, the local fit in the low-dose range, that is, the doses nearest the BMR, may be considered. In practice, different models often result in roughly similar BMDs, provided that they adequately describe the data. In any case, the results from different models and the choice of model should be discussed.

In some cases, it may be necessary to exclude high dose data from the model fitting procedure, to improve the goodness of fit. Data at the highest doses of a multiple dose bioassay may be considered to be less informative for the purpose of low dose extrapolation, especially in cases where the responses plateau at the high doses. Therefore, high dose groups may be systematically eliminated until the fit is acceptable (Anderson 1983).

In other cases, such as when a non-monotonic dose response is observed, none of the dose response models may be able to fit the data adequately. When this occurs, the BMD approach should not be used. While the NOAEL/LOAEL approach could still be applied, the quality of the study should be given careful consideration. It may not be appropriate to derive an ADI by any method from such a data set.

The steps for estimating the BMD may be summarized as follows:

- Select the bioassay(s) and endpoint(s) to model.
- Determine whether the data are quantal or continuous.
- Fit the bioassay data set(s) to several dose response models and determine the goodness of fit. Calculate multiple BMDs, including maximum likelihood estimates (MLEs) of risk and confidence limits. Graph the results.
- Select which model to use for determining the ADI. Generally, the model giving the best fit is used. If multiple models fit the data well, the local fit near the BMR may be considered. In some cases, the choice of model may be based on mechanistic

considerations. If no model fits the data adequately, the BMD approach should not be used.

- If multiple endpoints or bioassays are modeled, select which to use for determining the ADI. The most sensitive dose response is generally used (CPSC 1992, Section F.4.b.ii, page 46656). Other factors, such as severity of the effect may also be considered.
- Select which BMD (BMR) to use for deriving the ADI.
- Discuss and explain all of the decision points in the preceding steps.

### Statistical Methods

Various types of software may be used to estimate the BMD/BMDL. The U.S. Environmental Protection Agency (EPA) has developed Benchmark Dose Software (BMDS) specifically for this purpose (EPA 2022). The BMDS and associated documentation are in the public domain and may be downloaded from the EPA website. Software is also available from the Netherlands Ministry of the Environment (RIVM 2021) and Shao and Shapiro (2018). Various other statistical software packages (e.g., SAS, and R) may also be used. Likelihood methods are generally preferred for estimating the BMD and confidence limits (Crump 1984a; Crump and Howe 1985; Crump et al. 1995; Gaylor et al. 1998; EPA 2001). Goodness of fit is typically based on chi-square.

As with cancer risk assessment, CPSC staff prefers to use extra risk, rather than additional risk, as a measure of the risk over background. Extra risk applies Abbott's correction, so that animals which already have a given lesion from background processes are not considered at risk for an exposure-induced lesion of the same type. The numerical difference between extra risk and additional risk is small, provided that the background risk is sufficiently low (<0.25). Extra risk (Crump and Howe 1985) is defined by:

$$P_E = \frac{P_D - P_0}{1 - P_0} \quad (1)$$

where:  $P_E$  is the extra risk,  $P_D$  is the risk at dose  $D$ , and  $P_0$  is the background dose.

Additional risk is defined by:

$$P_A = P_D - P_0 \quad (2)$$

where:  $P_A$  is the additional risk.

### Selection of the Benchmark Dose (BMD)—Quantal Data

The ADI is the dose at which the risk of an adverse effect is considered negligible. Because such risks cannot be directly measured, this requires assumptions about the shape of the dose response curve in the low dose region. For cancer, there are theoretical reasons for assuming a linear response at low dose, such as the probability that a given chemical will interact with background processes or other chemicals (CPSC 1992, VI.F.3.b.ii, page 46654). For non-cancer endpoints, a non-linear dose response is generally presumed, although the shape and slope of this curve outside of the observable range is unknown.

The selection of the BMD has been based on the following considerations: (i) The BMD should be within or near the observable range of the bioassay. (ii) It is roughly the dose at which a statistically significant effect may be observed in the bioassay (Crump et al. 1995). Thus, BMD's of 5% to 10% over background are typically used for quantal data, assuming that there is an adequate number of animals and the background level is not exceptionally high. (iii) The

BMD approach is an alternative to deriving the ADI from a NOAEL. The BMD has generally been selected to approximate the NOAEL (Crump et al. 1995). Thus, the study selected for estimating the BMD should include a dose at or near the NOAEL. Other factors, such as the shape of the dose response curve or the study design (e.g., CPSC 2001, 2002), may be considered on a case-by-case basis. For example, it may be desirable to select a BMD that is reflective of nonlinearity or an inflection point in the dose response curve (Murrell et al. 1998).

It is important to keep in mind that the selection of a BMD is part of the overall risk assessment process, which includes the selection of the critical endpoint and uncertainty factors, among other things. The overall process is equally as important as the individual steps. For example, the risk assessor might consider applying different uncertainty factors, depending on the BMD selected. That is, consideration could be given to larger or additional uncertainty factors if the BMD is higher than is typical, or to smaller uncertainty factors if the BMD is exceptionally low.

Numerous authors (Barnes et al. 1995; Crump 1984a; Filipsson et al. 2003) and the EPA (EPA 2005) generally recommend using the 95% lower confidence limit (LCL) of the benchmark, typically the  $BMDL_{05}$  or  $BMDL_{10}$ . This generally satisfies the criteria listed above. In a typical bioassay, the LCL is within or near the observable range, it is near the lowest detectable response, and it is roughly equivalent to the NOAEL. Using the LCL takes into account the uncertainty in the bioassay and tends to reward larger or better studies, which generally have narrower confidence intervals. On the other hand, it has been argued that using the LCL rather than the best estimate (maximum likelihood estimate or MLE) leads to a BMD that may depend more on experimental uncertainty than on the dose response itself (Murrell et al. 1998). Thus, using the LCL tends to defeat one of the principal advantages of the BMD approach, which is to make use of the shape and slope of the dose-response curve in the analysis.

While the choice of the BMD should be made on a case-by-case basis, it is desirable to have a default value for the purpose of consistency across different chemicals, endpoints, and risk assessors. However, even if the default value is used, the risk assessor must evaluate whether the default is appropriate in a given case, using the criteria described above. Risk assessors have most frequently used  $BMDL_{05}$  or  $BMDL_{10}$  to derive ADIs (or RfDs) (see above). The Chronic Hazard Advisory Panel (CHAP) convened by CPSC (CPSC 2001) and CPSC staff (CPSC 2002) used the  $BMD_{05}$  to set an ADI level for diisononyl phthalate. Health Canada also uses the  $BMD_{05}$  to set tolerable intake levels. One advantage of using the MLE is that it is more reflective of the shape of the dose response than the LCL (Murrell et al. 1998).

For cancer risk assessment, CPSC prefers to use the MLE risk (see below). However, as currently applied, the ADI is not regarded as a numerical estimate of risk, as is the case for cancer risk. Rather, it is regarded as a regulatory threshold, that is, a “negligible risk level” or “virtually safe dose.” Therefore, the reasons for using the MLE to estimate cancer risk do not necessarily apply to ADIs. This conclusion may change in the future, if true risk-based approaches are applied to non-cancer endpoints.

At the present time it seems reasonable to use the  $BMD_{05}$  (i.e., the MLE) rather than the  $BMDL_{05}$  (i.e., the LCL) as a default value, subject to the limitations discussed above. This is consistent with the CPSC approach to estimating cancer risk and with previous CPSC applications of the BMD approach. In addition, the MLE better reflects the shape of the dose response, as compared to the LCL.

### **Selection of the Benchmark Dose (BMD)—Continuous Data**

For continuous data, the BMD value is generally a level that is considered “adverse.” This is a matter of professional judgment by health scientists, such as toxicologists and pathologists, and must be determined on a case-by-case basis. As discussed in the previous section on

“Selection of the Benchmark Dose (BMD)—Quantal Data,” the MLE value is preferred for risk assessment. In instances where there is no consensus on what constitutes an adverse effect, some risk assessors have used a relative change in the endpoint, such as a change of one standard deviation.

### Cancer Risk Assessment

The multistage model (Crump 1984b) has been preferred by most federal agencies for cancer risk assessment. The multistage model is defined by:

$$P_D = 1 - e^{-[q_0 + q_1 D + q_2 D^2 + \dots + q_9 D^9]} \quad (3)$$

where: D, dose;  $P_D$ , cancer risk at dose D; and  $q_0 \dots q_9$ , parameters to be fitted by the model.

The EPA has preferred to use the upper confidence limit (UCL) of the estimated risk, while CPSC staff uses the MLE risk, unless the linear term ( $q_1$ ) is zero. When  $q_1$  is zero, the UCL risk is used to ensure linearity at low doses (CPSC 1992, VI.F.3.b.ii, page 46654).

EPA began to use the BMD approach for cancer risk assessment in place of the multistage model in 2005 (EPA 2005). BMD is the preferred method for dose response assessment at EPA and other agencies (Allen et al. 2011). The default procedure is to use the BMR as a point of departure (PoD) for linear extrapolation to the background level. Uncertainty factors may be applied if there is sufficient reason to rule out a linear dose response at low doses. This procedure is analogous to the Mantel-Bryan procedure (Mantel & Bryan 1961; see also Gaylor & Kodell 1980) that was commonly used before the multistage model became available.

The BMD approach described by EPA is consistent with the default procedures used by CPSC staff under the guidelines. The primary concern of CPSC staff is that linear extrapolation should remain as the default procedure for guidelines purposes. The results from using the BMD methodology and the multistage model are not substantially different when linear extrapolation is assumed. In general, a non-linear dose response with use of uncertainty factors should be used only if there is convincing evidence that the dose response is non-linear at low doses. In addition, the BMD approach offers certain advantages over the multistage model as applied by CPSC staff. While staff prefers to use the MLE estimate of cancer risk, it is necessary to use the UCL risk in cases where the linear term ( $q_1$ ) is zero. By using the BMD approach, the MLE risk can be used in all cases. Thus, the process is simplified. In addition, staff use the BMD approach for non-cancer endpoints, BMD methods are used by EPA and other agencies for both cancer and non-cancer risk assessment, and the software is widely available.

The practice of the CPSC Directorate for Health Sciences (HS) is to present the best estimate of risk, rather than the upper bound, to risk managers. Thus, HS prefers the MLE of risk in cancer risk assessments (CPSC 1992, § VI.F.3.b.iii). Presenting the best estimate of risk depends on a number of considerations: (i) CPSC does not routinely define “safe” levels, as is frequently done by other agencies such as the Food and Drug Administration (FDA) and EPA. Rather, the need for CPSC actions based on unsafe levels are typically determined on a case-by-case basis. (ii) For typical cancer bioassays in animals, the difference between the MLE and 95% upper confidence limit (UCL)<sup>9</sup> is generally small, about 2- to 3-fold. (iii) The overall risk assessment process is designed to include assumptions that tend to err on the side of safety when data are lacking for a particular part of the assessment. Thus, there is always a possibility of compounding safety assumptions which could result in some cases in unrealistic estimates.

<sup>9</sup> The UCL risk corresponds to the LCL dose.

Therefore, the use of the MLE rather than the UCL generally has a small effect on numerical estimates.

Therefore, the BMD approach with linear extrapolation and based on the MLE risk generally will be the default procedure for cancer risk assessments performed by CPSC staff. To further simplify the process, the multistage (polynomial) model generally will be the default model for cancer risk. However, other models that adequately describe the data may be used, as described above for non-cancer endpoints. While the choice of a PoD is not critical, the default will be the BMD<sub>05</sub> (see above). Although the BMD approach will be the default procedure, the multistage model, as described above, can still be used. Risk assessors may deviate from the default assumptions described in the guidelines, provided that their methods and assumptions are documented, scientifically defensible, and supported by appropriate data (CPSC 1992, § VI.A.2).

The following practices are recommended when applying benchmark dose methodology:

- The BMD approach is generally the preferred method for setting ADI levels for non-cancer endpoints, provided that adequate dose response data are available.
- Appropriate dose response models and statistical methods have been described in detail elsewhere (Crump 1984a; Crump et al. 1995). Public domain software is available from EPA (EPA 2022).
- The BMD response level (BMR) used to calculate the ADI will be determined on a case-by-case basis. A range of BMR's, including best estimates and lower confidence limits, should be considered.
- As a default, CPSC staff will use the maximum likelihood estimate of the dose at which the extra risk is 5% (BMD<sub>05</sub>). The same uncertainty factors currently applied to the NOAEL will be applied to the BMD.
- Several dose response models should be considered. Generally, the model that best describes the observed dose response data will be selected to derive the ADI. In addition, the ADI will generally be based on the combination of dose response model, endpoint, and study that lead to the lowest ADI.
- Risk assessors may deviate from the default assumptions described in the guidelines, provided that their methods and assumptions are documented, scientifically defensible, and supported by appropriate data (CPSC 1992, § VI.A.2). While the BMD approach is typically preferred, the traditional method based on NOAELs/LOAELs may still be used.

In addition, the BMD approach with linear extrapolation and based on the MLE risk will be the default procedure for cancer risk assessments performed by CPSC staff. The multistage (polynomial) model will be the default model for cancer risk. However, other models that adequately describe the data may be used, as described above for non-cancer endpoints. While the choice of a PoD is not critical, the default will be the BMD<sub>05</sub>. Linear extrapolation from the PoD generally will be used unless there is convincing evidence that the dose response will be non-linear at low doses (CPSC 1992, VI.F.3.b.ii, page 46654). In cases where a non-linear dose response is justified, uncertainty factors may be applied as described for non-cancer endpoints. Although the BMD approach will be the preferred procedure, the multistage model, as traditionally applied by CPSC, can still be used.

## SUMMARY

### Estimation of the Acceptable Daily Intake for Non-Cancer Endpoints

The following supplements the guidance on estimating acceptable daily intakes (ADIs) in the CPSC Chronic Hazard Guidelines at 57 FR 46,656 (Oct. 9, 1992) in § VI.F.4.b.1.ii, and the summary in 16 CFR §1500.135(d)(4)(ii)(B). This does not supersede the 1992 guidance; rather, it provides guidance on the use of newer methods for estimating ADIs.

Traditionally, CPSC staff derived acceptable daily intake (ADI) levels for non-cancer endpoints by applying safety factors (uncertainty factors) to the no-observed-effect level (NOAEL) or lowest-observed-effect-level (LOAEL). However, the benchmark dose (BMD) approach is now generally preferred over the traditional method. The benchmark dose is an estimate of the dose at a certain risk level. The BMD is estimated from a dose-response model. The advantages of the BMD approach and methods for estimating the BMD are described elsewhere (Barnes et al. 1995; Crump 1984; Crump et al. 1995; EPA 2012; Filipsson et al. 2003; Gaylor et al. 1998). Software for estimating the BMD is available from the U.S. EPA (EPA 2022) and other sources. In estimating the BMD, the risk assessor should consider the following points: (a) The dose-response model must provide an adequate fit to the data; the BMD approach may not be appropriate for all data sets. (b) Alternative dose response models should be considered, and the choice of model to derive the ADI explained. (c) Alternative endpoints and studies should also be considered, as appropriate. (d) A range of BMD response levels, including best estimates and confidence intervals should be evaluated. (e) Generally, different methods are required for dichotomous and continuous data.

The BMD selected to derive the ADI (BMD response level) is determined on a case-by-case basis. The BMD response level (BMR) must be within or near the range of experimental dose levels. As a default, for dichotomous (i.e., incidence) data, the BMR will be the maximum likelihood estimate of the dose associated with an extra risk (risk over background) of 5% (BMD<sub>05</sub>). For continuous data, (e.g., enzyme or hormone levels), the BMD is generally based on the level considered to be an adverse effect. The default safety (uncertainty) factors described above (10-fold for human data and 100-fold for animal data) are applied to the BMD CPSC 1992, §VI.F.4.b.1.ii; Haber et al. 2018). Thus, the ADI is generally 100-fold lower than a BMD based on animal data. An additional uncertainty factor for ADIs based on a LOEL is not needed. While the BMD approach is preferred, the traditional method of applying safety factors to the NOAEL or LOAEL may still be used.

### Estimation of Cancer Risk

The following is a supplement to the CPSC Chronic Hazard Guidelines at FR 57: 46654. § VI.F.3.b.ii. October 9, 1992, and the summary at 16 CFR §1500.135 (d) (4) (ii) (B).

Traditionally, CPSC staff estimated cancer unit risks (slope factors) using the multistage model (Global83). The maximum likelihood estimate (MLE) of risk was used unless the linear term ( $q_1$ ) was equal to zero; in this case, the upper confidence limit of risk was used. However, the benchmark dose (BMD) approach with linear extrapolation based on the MLE risk is now generally preferred over the traditional method. The multistage (polynomial) model will be the default model for cancer risk. However, other models that adequately describe the data may be used, as described above for non-cancer endpoints. The choice of a BMD response level (BMR) or point-of-departure (PoD) will be made on a case-by-case basis. In general, the

default PoD will be the MLE estimate of the dose associated with an extra risk (risk over background) of 5% ( $BMD_{05}$ ). Linear extrapolation from the PoD will be used unless there is convincing evidence that the dose response will be non-linear at low doses. In cases where a non-linear dose response is justified, uncertainty factors may be applied as described for non-cancer endpoints. Although the BMD approach generally is preferred under the guidelines, the traditional CPSC approach based on the multistage model may still be used.

## REFERENCES

- Allen JA, Gift JS, Zhao QJ (2011) Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1. *Toxicology and Applied Pharmacology* 254: 181-191
- Anderson EL (1983) Quantitative approaches in use to assess carcinogenic risk. *Risk Analysis*, 3: 277-295.
- Barnes DG, Daston GP, Evans JS, Jarabek AM, Kavlock RJ, Kimmel CA, Park C, Spitzer HL (1995) Benchmark Dose Workshop: criteria for use of a benchmark dose to estimate a reference dose. *Regulatory Toxicology and Pharmacology* 21: 296-306.
- Consumer Product Safety Commission (CPSC) (1992) Labeling requirements for art materials presenting chronic hazards; guidelines for determining chronic toxicity of products subject to the FHSA; supplementary definition of "toxic" under the Federal Hazardous Substances Act; final rules. *Federal Register* 57: 46626-46674. October 9, 1992. [https://www.cpsc.gov/s3fs-public/pdfs/blk\\_pdf\\_chronichazardguidelines.pdf](https://www.cpsc.gov/s3fs-public/pdfs/blk_pdf_chronichazardguidelines.pdf).
- Consumer Product Safety Commission (CPSC) (2001) Chronic Hazard Advisory Panel on Diisononyl Phthalate (DINP). U.S. Consumer Product Safety Commission, Bethesda, MD 20814. June 2001. <http://www.cpsc.gov/library/foia/foia01/os/dinp.pdf>.
- Consumer Product Safety Commission (CPSC) (2002) Updated risk assessment of oral exposure to diisononyl phthalate (DINP) in children's products. U.S. Consumer Product Safety Commission, Bethesda, MD 20814. August 2002. <http://www.cpsc.gov/library/foia/foia02/brief/briefing.html> (TAB L).
- Crump KS (1984a) A new method for determining allowable daily intakes. *Fundamental and Applied Toxicology* 4: 854-871.
- Crump KS (1984b) An improved procedure for low-dose carcinogenic risk assessment from animal data. *Journal of Environmental Pathology, Toxicology and Oncology* 5: 339-348
- Crump KS, Allen BA, Faustman E (1995) The Use of the Benchmark Dose Approach in Health Risk Assessment. *Risk Assessment Forum*, U.S. Environmental Protection Agency, Washington, DC 20460. February 1995. EPA/630/R-94/007. <https://www.epa.gov/nscep>
- Crump KS, Howe RB (1985) A review of methods for calculating statistical confidence limits in low dose extrapolation. In "Toxicological Risk Assessment," Volume I. Clayson DB, Krewski D, Munro I, editors. CRC Press, Boca Raton, FL. Pages 187-203.
- Environmental Protection Agency (EPA) (2022) Benchmark Dose Tools. U.S. Environmental Protection Agency, Washington, DC 20460. <https://www.epa.gov/bmds>. Accessed January 4, 2022.
- Environmental Protection Agency (EPA) (2012) Benchmark Dose Technical Guidance Document—External Review Draft. *Risk Assessment Forum*, U.S. Environmental Protection Agency, Washington, DC 20460. June 2012. EPA/630/R-12/001. [https://www.epa.gov/sites/default/files/2015-01/documents/benchmark\\_dose\\_guidance.pdf](https://www.epa.gov/sites/default/files/2015-01/documents/benchmark_dose_guidance.pdf)
- Environmental Protection Agency (EPA) (2005) Guidelines for Carcinogen Risk Assessment. *Risk Assessment Forum*, U.S. Environmental Protection Agency, Washington, DC 20460. March 2005. EPA/630/P-03/001B. <https://www.epa.gov/sites/default/files/2013->



[09/documents/cancer\\_guidelines\\_final\\_3-25-05.pdf](#)  
<https://www.epa.gov/risk/guidelines-carcinogen-risk-assessment>

- Filipsson AF, Sand S, Nilsson J, Victorin K (2003) The benchmark dose method—review of available models, and recommendations for application in health risk assessment. *Critical Reviews in Toxicology* 33: 505-542.
- Gaylor DW, Kodell RL (1980). Linear interpolation algorithm for low dose risk assessment of toxic substances. *Journal of Environmental Pathology and Toxicology* 4: 305-12.
- Gaylor D, Ryan L, Krewski D, Zhu Y (1998) Procedures for calculating benchmark doses for health risk assessment. *Regulatory Toxicology and Pharmacology* 28: 150-164.
- Haber LT, Dourson ML, Allen BC, Hertzberg RC, Parker A, Vincent MJ (2018) Benchmark dose (BMD) modeling: current practice, issues, and challenges. *Critical Reviews in Toxicology* Volume 48, 2018 - Issue 5
- Mantel N, Bryan WR (1961) "Safety" testing of carcinogenic agents. *Journal of the National Cancer Institute* 27: 455-70.
- Murrell JA, Portier CJ, Morris RW (1998) Characterizing dose-response I: critical assessment of the benchmark dose concept. *Risk Analysis* 18: 13-26.
- RIVM (2021) PROAST. National Institute for Public Health and the Environment (RIVM), The Netherlands. September 2021. <https://www.rivm.nl/en/proast>
- Shao K, Shapiro RJ (2018) A Web-Based System for Bayesian Benchmark Dose Estimation. *Environmental Health Perspectives* 126(1): 017002.  
<https://ehp.niehs.nih.gov/doi/10.1289/EHP1289>
- Zeise L, Wilson R, Crouch EAC (1987) Dose-response relationships for carcinogens: a review. *Environmental Health Perspectives* 73: 259-308.

**TAB B: Draft Supplemental Guidance for the Analysis of  
Uncertainty and Variability in Risk Assessment**

**T  
A  
B  
  
B**

# DRAFT SUPPLEMENTAL GUIDANCE FOR THE ANALYSIS OF UNCERTAINTY AND VARIABILITY IN RISK ASSESSMENT<sup>10</sup>

## BACKGROUND

In 1992, the U.S. Consumer Product Safety Commission (CPSC) issued guidelines for assessing chronic hazards under the Federal Hazardous Substances Act (FHSA), including carcinogenicity, neurotoxicity, reproductive/developmental toxicity, exposure, bioavailability, risk assessment, and acceptable risk. The guidelines are detailed in a *Federal Register* notice (57 FR 46,626, Oct. 9, 1992) (CPSC 1992) and are summarized at 16 C.F.R. § 1500.135. The chronic hazard guidelines are intended as an aid to manufacturers in making their determination of whether a product is a hazardous substance due to chronic toxicity, and thus would require labeling under the FHSA. The guidelines are not mandatory. The guidelines describe standard methods CPSC staff may use to assess chronic hazards under the FHSA. The guidelines are intended to be sufficiently flexible to incorporate the latest scientific information, such as advances in risk assessment methodology. Therefore, CPSC staff initiated reviews of the existing guidelines and is recommending additions or changes, as appropriate. The purpose of this document is to describe supplemental guidance for the analysis of uncertainty and variability in risk assessment, including the use of probabilistic techniques.

## DISCUSSION

In toxicological risk assessment, uncertainty is the term used to describe the lack of knowledge in the underlying science, such as when few measurements of the particular subject have been made. Uncertainty may also be associated with the choice of mathematical model used to estimate exposure or risk. Variability refers to inherent differences due to heterogeneity or diversity in the population or exposure variable, such as body weight of people in the exposed population. Variability is generally not reducible by improved measurement or further study (EPA 1997, 2014).

The theory and techniques of exposure assessment have been discussed in detail elsewhere (CPSC 1992; EPA 2014, 2019; Paustenbach 2002). Exposure may be measured directly, but, in general, an exposure assessment is often based on a mathematical model that combines several variables describing the factors that influence exposure. For example, an assessment of exposure to a chemical released into the air during use of a product will include information about the emission rate into the air, the resulting concentration of the chemical in the air, the amount of time a person using the product or spent living, working, or playing in the area, and the amount of air a person breathes during the exposure. For a given exposure scenario, the output of an exposure assessment is typically an estimate of the amount of chemical that comes into contact with the body, usually expressed per unit of body weight per day during a defined period of time or over a lifetime, although exposure may be defined in other terms.

For carcinogens, “risk” is the product of the exposure estimate and the dose-response value, *i.e.*, the numerical representation of cancer risk per unit of daily exposure. For non-carcinogens,

---

<sup>10</sup> These draft guidelines were developed by CPSC staff, have not been reviewed or approved by, and may not reflect the views of, the Commission.

the exposure estimate is compared with the “acceptable daily intake” (ADI), which is the level of exposure at which we expect humans not to experience harmful health effects. Although there is no numerical estimate of “risk” in this latter case, one may calculate the hazard index (HI), which is the ratio of the estimated exposure to the ADI (HI greater than one means that the exposure may be hazardous; HI less than one represents negligible risk).

There is no single, correct way to conduct an exposure or risk assessment for purposes of evaluating chronic hazards under the Federal Hazardous Substances Act (FHSA) or the Labeling of Hazardous Art Materials Act (LHAMA). There are, however, important issues and concerns that are commonly encountered in risk assessment that should be considered regardless of the specific risk assessment approach. Because risk assessment is a rapidly advancing field, the discussions here should be supplemented with other information from the scientific literature, texts, and government agency guidance, as scientifically appropriate.

In most cases, the risk assessor will consider uncertainty and variability in the assessment and, at a minimum, include a discussion of the effect of uncertainty and variability on the final risk estimates. The discussion may be qualitative or it may include quantitative estimates of uncertainty and variability. Variability and uncertainty are distinct issues and should be considered separately in each analysis using appropriate statistical techniques, such as two-dimensional probabilistic analyses (Cullen and Frey 1999). In practice, however, increasingly complex analyses may not be warranted for every situation, as discussed below. In addition, the available data may not be sufficient to distinguish between variability and uncertainty or to allow statistical consideration of both issues.

Risk assessors may take one of two general approaches to conduct risk assessments: deterministic or probabilistic (stochastic) modeling. Of these, probabilistic techniques explicitly include quantification of uncertainty and variability.

Risk analyses have long been grounded on deterministic approaches. Probabilistic risk assessments have been used for many years in predicting accidents and systems failures, and in weather forecasting. Over time, probabilistic approaches have been applied to ecological and human health risk assessments (Kendall *et al.*, 2001).

Deterministic and probabilistic modeling are both valid mathematical approaches for estimating risk. The key difference between these approaches is that deterministic modeling enters point estimates (*i.e.*, single values) for the model’s inputs while probabilistic modeling uses probability distributions for some or all inputs in conjunction with statistical techniques such as Monte Carlo analysis. Consequently, the output of a deterministic assessment is a point estimate of the exposure or risk for the exposed individual or population. A probabilistic approach results in a distribution of exposure or risk estimates, which may provide additional information about the variability in the exposure of interest and the uncertainty in the analysis or of the true, but unknown risk.

Exposure and risk assessments are conducted for many different reasons, such as to answer specific questions about exposure scenarios, inform decision-making, and explore options. The ultimate application of the assessment will help determine the methodological approaches and techniques to be used. The choice of approach may be based on considerations of the available scientific information, institutional policies, time and resources available, or social implications.

Risk assessments may be iterative, *e.g.*, subject to collection of new data or refinement of existing data. Assessments may be conducted in a tiered approach, in which each analysis is based on the knowledge and resources available to the risk assessor and the needs of decision-makers and stakeholders. In general, risk analysts will work from the simple to the

complex until, for example, the problem has been sufficiently characterized so that risk managers may proceed with decision-making and initiate any actions required to manage the hazard. An initial analysis may be conducted to determine whether a given exposure scenario is associated with relatively high or relatively low risk. For example, protective assumptions are sometimes used initially to characterize the level of risk. If such an assessment indicates a relatively high risk, the analyst may choose to collect more data or conduct a more complex assessment in order to verify the result before actions are taken. An initial analysis may also be used to identify insignificant exposure pathways that do not require further consideration.

In many cases, deterministic techniques may be more desirable than probabilistic methods, particularly for such early analyses that are often under time and resource constraints, because probabilistic methods can be more complex, time-consuming, and costly. On the other hand, risk managers may find that more sophisticated techniques, including probabilistic methods, are valuable in providing certain detailed information about the risks in the exposed population, to explore the uncertainty in the true, but unknown risk to an individual, or for systematically analyzing variability, uncertainty, pathways of exposure, or alternative models. The risk assessor and risk manager must consider the utility of the risk assessment result and determine the value added by each assessment choice that increases the time, cost, and complexity of the assessment.

Ultimately, a risk assessment is conducted to gain insight into the exposures and risks associated with a given scenario. See section VI.F. of the guidelines (CPSC 1992). Each assessment should be approached on a case-by-case basis, consistent with the requirements of the risk assessor and risk manager. Regardless of the risk analysis approach, the quality of the assessment depends on the quality and availability of relevant data.

In general, for a given body of knowledge, a deterministic assessment that is based predominantly on central tendency values for each of the input variables (*e.g.*, a best estimate of the available data, such as a mean or median), may provide results similar to a probabilistic assessment that is based on the same underlying information. However, risk analysts must be aware of the effects of decisions regarding the use of the available data and assumptions. For example, a deterministic analysis that uses multiple protective values rather than central values may lead to unintentionally precautionous results, *i.e.*, compounding safety factors. In addition, for a distribution of data that is skewed to the right, the mean will be represented by a value in the right tail and could be considerably larger than the median. In such a case, the mean could also be considered a protective value.

The primary advantage of a probabilistic approach is the generation of information on the distribution of exposure and risk in a population, in addition to estimates of the average exposure and risk. This provides information on the range of exposures, including highly exposed individuals. However, the risk analyst must consider that sparse data or a poorly fitting distribution to the data for one or more model inputs could lead to inappropriate conclusions about the resulting distribution, particularly at the tails of the distribution, which may be most sensitive to deficiencies in the data. Further, a probabilistic model may be sensitive to correlations between input variables (*e.g.*, body weight and body surface area). Discussion of the presence of correlations and dependence among variables and their effects on the output should be included in the assessment.

Another advantage of probabilistic techniques is the ability to derive confidence intervals for exposure estimates. Thus, in addition to estimating the mean, median, and 95<sup>th</sup> percentiles of exposure, one may also estimate confidence intervals for these estimates, expressed as  $X \pm Y$ , which provides a measure of uncertainty in the estimated exposure. It also gives the risk assessor and risk manager information on the reliability of exposure estimates. Typically, the

confidence intervals will be larger in the tails of the distribution, *i.e.*, confidence intervals for the 95<sup>th</sup> or 99<sup>th</sup> percentile of the distribution may be larger than the confidence interval about the mean. Therefore, whenever possible, methodology that permits the estimation of confidence intervals should be applied.

Currently, probabilistic techniques are used primarily in estimating exposure, while single point estimates are derived to describe the dose-response (*i.e.*, unit risk for carcinogens; ADI for non-carcinogens). The application of probabilistic methods to deriving unit risks and ADIs is not presently in widespread use, although this has been encouraged by the National Research Council (NRC 2009).

A distinct issue, but related to analysis of uncertainty, is sensitivity analysis. Sensitivity analysis is used to identify variables that have the largest effect on the assessment output, and general approaches and statistical techniques have been developed for both deterministic and probabilistic analyses. It is often useful to know if small changes in the values for some variables result in relatively large changes in the output. For example, such an analysis may be used to identify areas of research that could improve future risk assessments. Sensitivity analysis may also be used to focus on specific subpopulations or exposure scenarios or to identify the most important routes of exposure.

Such techniques also are useful for providing additional information in a deterministic assessment. That is, a separate sensitivity analysis can be used in conjunction with a deterministic approach to characterize the range of the most likely estimates of exposure and risk (*e.g.*, one technique is to vary key input variables, one at a time, throughout their reasonable range of values, while holding other inputs constant).

Recent exposure and risk assessments conducted by CPSC staff have used both deterministic and probabilistic methods based on the factors discussed above. For example, staff used probabilistic techniques to estimate the exposure and risk from oral intake of diisononyl phthalate by children from mouthing soft plastic toys and other objects, based on the strength of the available data (Babich 2002; Babich et al. 2004; Babich et al. 2020; Greene 2002). Yet staff used a deterministic approach with a separate uncertainty analysis to assess children's exposure to arsenic from wooden playground equipment treated with chromated copper arsenate (Hattelid 2003), because staff concluded that the data for several key input variables were insufficient to support a probabilistic analysis. In this case, mainly central tendency values were used to estimate the exposure, and a separate uncertainty analysis provided additional information about the likely range of exposure.

Section VI.F.4.b.i. of the guidelines (CPSC 1992) states that a carcinogenic risk of one per million or less is the appropriate level for defining acceptable risk<sup>11</sup>; *i.e.*, when exposure to an agent occurs, the exposed individual has an estimated excess risk of one chance in a million of developing cancer during his/her lifetime. In a deterministic analysis, one per million is compared directly with the risk value that results from the analysis. Section VI.F.1.d. of the guidelines also states that in most cases the best estimate of exposure, rather than a protective estimate, is acceptable.

Probabilistic analyses, however, result in distributions of exposure and risk. While there are no generally accepted guidelines for interpretation of results from probabilistic analyses for carcinogens, this topic has received attention (Burmester 1996; Thompson 2002; NRC 2009). Thompson cautioned against setting "bright-line" criteria for use in any context, and Burmester also argued that the risk manager must consider all the characteristics of the distribution resulting from the probabilistic assessment and not just a single point or summary statistic. As

---

<sup>11</sup> 16 C.F.R. § 1500.135 (d)(4)(i)

an example of how one might evaluate probabilistic results, Burmaster suggested that one might consider the skewness of the resulting risk distribution; whether the median of the distribution exceeds the one per million acceptable risk level; whether the mean exceeds one per one hundred thousand; and whether the 95<sup>th</sup> percentile exceeds one per ten thousand.

CPSC staff agrees that it generally is appropriate to consider all of the characteristics of the risk distribution (*e.g.*, the mean, median, and upper bounds values and the shape of the distribution) in judging whether or not the results represent an acceptable risk. Because of the complexity of probabilistic analyses and the diversity of possible probabilistic risk assessment results, staff assesses that it would be difficult to impose a rigid procedure for interpreting the results of probabilistic assessments. Staff recommends, however, that the one per million acceptable risk level for carcinogens currently defined in the guidelines generally should also serve as a guide for interpreting probabilistic risk assessment results. Because staff generally uses best estimates for exposure rather than upper bounds, staff assesses that interpretation of probabilistic results should be based in part on the relationship of the central tendency estimate of the resulting distribution to the one per million acceptable risk level. However, upper bound estimates of exposure (*e.g.*, 95<sup>th</sup> percentile) may provide useful information for highly exposed individuals.

Section VI.F.4.b.ii. (CPSC 1992) specifies a process for evaluating the acceptable daily intake (ADI) for neurotoxicological and developmental/reproductive agents.<sup>12</sup> Staff uses these guidelines for other non-cancer effects, as well. The use of the ADI in a deterministic assessment is straightforward—the estimated exposure is compared with the ADI. As is the case with cancer risk assessment, there are no standard guidelines for interpretation of results from probabilistic analyses of non-cancer effects. Following the reasoning for cancer assessments given above, staff recommends that interpretation of probabilistic results for non-cancer effects should be based in part on comparing the central tendency estimate of the outcome to the acceptable daily intake, similar to the case for deterministic assessments. However, upper bound estimates of exposure (*e.g.*, 95<sup>th</sup> percentile) may provide useful information for highly exposed individuals.

Because the guidelines are not binding rules, they are meant to be flexible and amenable to expert judgment, as well as continuing scientific advances. The guidance for interpretation of both cancer and non-cancer exposure and risk are intended to facilitate the assessment process, but in practice, risk assessors and risk managers will consider the specific information in each case in defining acceptable exposure and risk.

---

<sup>12</sup> 16 C.F.R. § 1500.135 (d)(4)(ii)

# SUMMARY

## Analysis of Uncertainty and Variability

The following supplements the guidance on exposure assessment in the CPSC Chronic Hazard Guidelines at 57 FR 46,644 (Oct. 9, 1992) in § VI.F.1 and the summary at 16 CFR § 1500.135(d)(1). It does not supersede the 1992 guidance; rather, it provides guidance on the use of probabilistic methods as an alternative method for exposure assessment.

Risk assessments may incorporate uncertainty (the lack of knowledge in the underlying science or in the choice of mathematical model) and variability (inherent differences due to heterogeneity or diversity in the population or exposure variable). The discussion may be qualitative or include quantitative estimates of uncertainty and variability. While variability and uncertainty are distinct issues and should be considered separately in each analysis, in practice, the available data may not be sufficient to distinguish between them.

Risk assessments may be based on deterministic or probabilistic modeling. Probabilistic modeling uses probability distributions for some or all inputs in conjunction with statistical techniques such as Monte Carlo analysis, and results in a distribution of exposure or risk estimates, providing quantification of uncertainty and variability. Deterministic modeling enters point estimates for the model's inputs and results in a point estimate of the exposure or risk. Separate uncertainty analysis may be used with a deterministic approach to characterize the range of the most likely exposure and risk.

Because exposure and risk assessments are conducted for different reasons, the ultimate use of the assessment results will help determine the methodological approaches and techniques to be used. The choice of approach may be based on considerations of the available scientific information, institutional policies, available time and resources, and limitations of the methods. For example, deterministic techniques may be appropriate for initial analyses that are often under time and resource constraints; however, the use of multiple protective values in a deterministic analysis may lead to unintentionally protective results, *i.e.*, compounding safety factors. A probabilistic assessment may be used to generate information on the distribution of exposure and risk in a population or to explore the uncertainty in the true, but unknown risk to an individual, but the risk assessor must consider that sparse data or poorly fitting distributions to the data for one or more model inputs could lead to inappropriate conclusions about the results, particularly at the tails of the distribution, which may be most sensitive to deficiencies in the data. A probabilistic model may be sensitive to correlations between input variables; the presence of correlations and dependence among variables and their effects on the output should be considered.

A carcinogenic risk of one per million or less is the guidelines' default level for defining acceptable risk (16 C.F.R. § 1500.135(d)(4)(i)). In a deterministic analysis, one per million is compared directly with the risk value that results from the analysis. Interpretation of probabilistic results should be based in part on the relationship of the central tendency estimate (*e.g.*, mean or median, as appropriate for the specific distribution) to the one per million acceptable risk level, but all characteristics of the resulting distribution should be considered.

For assessment of non-carcinogens in a deterministic assessment, the exposure estimate is compared directly with the ADI, or the hazard index (HI) is calculated as the ratio of the estimated exposure to the ADI (HI greater than one means that the exposure may be hazardous; HI less than one represents negligible risk). Probabilistic results should be interpreted in part by comparing the central tendency estimate to the acceptable daily intake, but all characteristics of the resulting distribution should be considered.



The guidance for interpretation of both cancer and non-cancer exposure and risk are intended to facilitate the assessment process, but in practice, risk assessors and risk managers will consider the specific information in each case in defining acceptable exposure and risk.

## REFERENCES

- Babich MA. 2002. Updated risk assessment of oral exposure to diisononyl phthalate (DINP) in children's products. In: Response to Petition HP 99-1. Request to Ban PVC in Toys and Other Products intended for Children Five Years of Age and Under. U.S. Consumer Product Safety Commission. Washington, DC 20207. August 2002. <http://www.cpsc.gov/library/foia/foia02/brief/briefing.html> (TAB L).
- Babich MA, Greene MA, Chen S, Porter WK, Kiss CT, Smith TP, Wind ML. 2004. Risk assessment of oral exposure to diisononyl phthalate from children's products. *Regulatory Toxicology and Pharmacology* 40: 151-167.
- Babich MA, Bevington C, Dreyfus M (2020) Plasticizer migration from children's toys, child care articles, art materials, and school supplies. *Regulatory Toxicology and Pharmacology* 111: 104574.
- Burmester DE. 1996. Benefits and Costs of Using Probabilistic Techniques in Human Health Risk Assessments—with an Emphasis on Site-Specific Risk Assessments. *Human and Ecological Risk Assessment* 2(1): 35-43.
- Consumer Product Safety Commission (CPSC). 1992. Labeling requirements for art materials presenting chronic hazards; guidelines for determining chronic toxicity of products subject to the FHSA; supplementary definition of "toxic" under the Federal Hazardous Substances Act; final rules. 57 *Fed. Reg.*: 46626-46674 (9 October 1992). [https://www.cpsc.gov/s3fs-public/pdfs/blk\\_pdf\\_chronichazardguidelines.pdf](https://www.cpsc.gov/s3fs-public/pdfs/blk_pdf_chronichazardguidelines.pdf).
- Cullen AC and Frey HC. 1999. *Probabilistic Techniques in Exposure Assessment: A Handbook for Dealing with Variability and Uncertainty in Models and Inputs*. New York: Plenum Press.
- Greene M. 2002. Oral DINP Intake Among Young Children. In: Response to Petition HP 99-1. Request to Ban PVC in Toys and Other Products intended for Children Five Years of Age and Under. U.S. Consumer Product Safety Commission. Washington, DC 20207. August 2002. <http://www.cpsc.gov/library/foia/foia02/brief/briefing.html> (TAB K).
- Hatlelid KM. 2003. Cancer risk assessment for arsenic exposure from CCA-treated wood playground structures. In: Re: Petition HP 01-3. Request to Ban Chromated Copper Arsenate (CCA)-Treated Wood in Playground Equipment. U.S. Consumer Product Safety Commission. Washington, DC 20207. February 2003.
- Kendall RJ, Anderson TA, Baker RJ, Bens CM, Carr JA, Chiodo LA, Cobb III GP, Dickerson, RL, Dixon, KR, Frame LT, Hooper MJ, Martin CF, McMurry ST, Patino R, Smith EE, Theodorakis CW. 2001. Ecotoxicology. In, *Casarett & Doull's Toxicology: The Basic Science of Poisons*. CD Klaassen, Ed. New York: McGraw-Hill.
- Morgan MG and Henrion M. 1990. *Uncertainty: A Guide to Dealing with Uncertainty in Quantitative Risk and Policy Analysis*. New York: Cambridge University Press.
- National Research Council (NRC). 1983. *Risk Assessment in the Federal Government: Managing the Process*. Washington, DC: National Academy Press.
- National Research Council (NRC). 2009. *Science and Decisions: Advancing Risk Assessment*. Washington, DC: The National Academies Press. <https://doi.org/10.17226/12209>. <https://www.nap.edu/download/12209>

- Paustenbach DJ (Ed.). 2002. *Human and Ecological Risk Assessment: Theory and Practice*. New York: John Wiley & Sons, Inc.
- Smith AE, Ryan PB and Evans JS. 1992. The Effect of Neglecting Correlations When Propagating Uncertainty and Estimating the Population Distribution of Risk. *Risk Analysis* 12(4): 467-474.
- Thompson KM. 2002. Variability and Uncertainty Meet risk Management and Risk Communication. *Risk Analysis* 22(3):647-654.
- U.S. Environmental Protection Agency (EPA). 2019. Guidelines for Exposure Assessment. Risk Assessment Forum, U.S. Environmental Protection Agency, Washington, DC. EPA/100/B-19/001. October 2019. [https://www.epa.gov/sites/default/files/2020-01/documents/guidelines\\_for\\_human\\_exposure\\_assessment\\_final2019.pdf](https://www.epa.gov/sites/default/files/2020-01/documents/guidelines_for_human_exposure_assessment_final2019.pdf)
- U.S. Environmental Protection Agency (EPA). 2014. Risk Assessment Forum White Paper: Probabilistic Risk Assessment Methods and Case Studies. Risk Assessment Forum, U.S. Environmental Protection Agency, Washington, DC. EPA/100/R-14/004. July 25, 2014. <https://www.epa.gov/sites/default/files/2014-12/documents/raf-pra-white-paper-final.pdf>
- U.S. Environmental Protection Agency (EPA). 1992. Guidelines for Exposure Assessment. Risk Assessment Forum, U.S. Environmental Protection Agency, Washington, DC. EPA/600Z-92/001.
- U.S. Environmental Protection Agency (EPA) 1997. Guiding Principles for Monte Carlo Analysis. EPA/630/R-97/001.
- U.S. Environmental Protection Agency (EPA). 2005. Guidelines for Carcinogen Risk Assessment. Risk Assessment Forum, U.S. Environmental Protection Agency, Washington, DC. March 2005. EPA/630/P-03/001B.